Sang‐Hee Cho

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Yoon‐Koo Kang, Jeong Hwan Yook, Young-Kyu Park et al. · Journal of Clinical Oncology · 2021 · 355 citations · Full text

Medicine, Oncology, Surgery +17

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

Rui‐Hua Xu, Kei Muro, Satoshi Morita et al. · The Lancet Oncology · 2018 · 160 citations

Medicine, Oncology, Pharmacology +15

Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk

Chenjie Zeng, Koichi Matsuda, Wei‐Hua Jia et al. · Gastroenterology · 2016 · 132 citations · Full text

Life Sciences, Genetics, Oncology +14

Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

Jun‐Eul Hwang, Dae‐Eun Kim, Hyun‐Jung Choi et al. · BMC Cancer · 2011 · 87 citations · Full text

Medicine, Oncology, Chemotherapy +16

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

Hyun Jeong Shim, Joo Young Yun, Jun‐Eul Hwang et al. · Cancer Science · 2010 · 75 citations · Full text

Medicine, Molecular Genetics, Oncology +16